Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > ACADEMIA
ACADEMIA
- Diovan Probe Updates to Come from Nagoya Univ. on Dec. 13, Chiba Univ. on Dec. 17
December 12, 2013
- New Hepatitis C Guidelines Set Triple Therapy Including Simeprevir as 1st Choice
December 11, 2013
- All Clinical Studies Should Follow GCP Requirements: Ex-AZ Chairman Kato
November 26, 2013
- Edoxaban Demonstrates Non-Inferiority to Warfarin in Stroke Prevention in AF Patients: Daiichi Sankyo
November 22, 2013
- AJMC Approves Draft of COI Management Guidelines
November 20, 2013
- JAMS COI Panel to Nudge JPMA to Create Funding Database
November 19, 2013
- JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials
November 19, 2013
- Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found
November 5, 2013
- Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study
November 1, 2013
- JSH2014 GL for Management of Hypertension to Emphasize Transparency, Remove References to Discredited Papers
October 29, 2013
- Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL
October 29, 2013
- Skills for Clinical Studies Required to Become Authorized Hypertension Specialist: JSH
October 28, 2013
- Kyoto Heart Study Chief Investigator to Leave JSH; JSH Ethics Committee Will Continue Investigation
October 28, 2013
- Japan’s First Guidelines for Hematological Malignancy Treatment Compiled by Japanese Society of Hematology
October 24, 2013
- President of Kyoto Prefectural University of Medicine Reprimanded Over Diovan Scandal, Diovan Study Chief Investigator Returns Retirement Allowance
October 17, 2013
- Shiga University of Medical Science to Unveil Diovan Probe Results at Month-End
October 16, 2013
- University of Tokyo Professor Says Results of Diovan Investigations Need to Be Made Open Globally
October 1, 2013
- National University Hospital Council Urges Immediate Check-Up on Hospital’s Clinical Research Systems
September 25, 2013
- AJMC to Unify COI Management Guidelines, Release Draft in December
September 24, 2013
- Use Double-Blind Method to Regain Confidence in Japanese Clinical Trials: Dr Yui of Kyoto Univ. Hospital
September 10, 2013
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…